Hairloss journey of 11 months on finasteride 12/27/2025
An 18-year-old male has been using finasteride for 11 months, minoxidil since September, dutasteride weekly, chelated iron supplements, and derma rolling, but his hair loss has worsened. He switched finasteride brands from Finalo and Finbald, and is concerned about decreased hair density.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Take finasteride NOW. Life is short.
User encourages taking finasteride for hair loss, stating rare permanent side effects. Replies discuss experiences with finasteride, side effects, effectiveness, and alternative treatments.
community Does the watery ejaculate issue ever resolve?
Dutasteride and finasteride can cause watery ejaculate, which may persist for some users. Zinc supplements or switching to topical treatments are suggested to alleviate this side effect.
community Does this look like hair regrowth at all?
The conversation is about hair regrowth, with the original poster using natural oils and supplements like pumpkin seed, saw palmetto, and zinc, while considering pharmaceutical options like minoxidil, finasteride, and dutasteride. Most users suggest using finasteride or dutasteride for effective results, as natural remedies are seen as ineffective.
community One month on oral fin. 20 years old. What the fuck is going on
A 20-year-old experiencing hair shedding after starting oral finasteride is advised to continue treatment and consider adding topical minoxidil. Shedding is normal, and patience is needed for hair regrowth.
community Crown Christmas Miracle: Back From the Dead 💀
A 42-year-old man achieved significant hair regrowth in seven months using oral minoxidil, oral dutasteride, topical minoxidil, microneedling, and supplements. He experienced minimal side effects and noted dramatic improvements in hair thickness and health.
Related Research
6 / 6 resultsresearch Interventions for female pattern hair loss
This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.
research Female pattern alopecia: current perspectives
This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.
research Guidelines based management of androgenetic alopecia
This review examines the effectiveness of current treatments for androgenetic alopecia, offering plastic surgeons evidence-based guidance for choosing safe and effective options, but reports no new results.
research A combination therapy for androgenic alopecia based on quercetin and zinc/copper dual-doped mesoporous silica nanocomposite microneedle patch
In this study, researchers developed a nanocomposite microneedle patch containing copper/zinc dual-doped silica nanoparticles, which release substances to promote hair follicle regeneration by targeting various pathophysiological aspects of androgenic alopecia, presenting an effective anti-hair loss treatment strategy.
research Plasma Zinc Levels in Males with Androgenetic Alopecia as Possible Predictors of the Subsequent Conservative Therapy’s Effectiveness
This study involving male patients with androgenic alopecia found that a higher baseline zinc plasma level, specifically above 10 µmol/L, may predict the success of treatment with 5% topical minoxidil, correlating with increased hair density and diameter in the parietal area.
research Focused Review on Metal Nanoparticles in Hair Regeneration and Alopecia: Insights into Mechanisms, Assessment Techniques, Toxicity, Regulatory and Intellectual Property Perspectives
This review explores the potential of metal nanoparticles as innovative treatments for alopecia, highlighting their effectiveness in promoting hair regrowth, enhancing drug delivery, and modulating gene expression while also assessing the related experimental methodologies and regulatory considerations.